title: Cancer radioimmunotherapy.
abstract: Targeting of radionuclides with antibodies, or radioimmunotherapy, has been an active field of research spanning nearly 50 years, evolving with advancing technologies in molecular biology and chemistry, and with many important preclinical and clinical studies illustrating the benefits, but also the challenges, which all forms of targeted therapies face. There are currently two radiolabeled antibodies approved for the treatment of non-Hodgkin lymphoma, but radioimmunotherapy of solid tumors remains a challenge. Novel antibody constructs, focusing on treatment of localized and minimal disease, and pretargeting are all promising new approaches that are currently under investigation.
authors.affiliation: Garden State Cancer Center, Belleville, NJ 07109, USA. rmsharkey@gscancer.org
authors.forename: Robert M
authors.initials: RM
authors.lastname: Sharkey
authors.forename: David M
authors.initials: DM
authors.lastname: Goldenberg
mesh_terms: D000818:Animals; D018033:Antibodies, Bispecific / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000532:radiotherapy; D009369:Neoplasms / Q000276:immunology / Q000532:radiotherapy; D016499:Radioimmunotherapy / Q000379:methods / Q000639:trends; D011868:Radioisotopes / Q000627:therapeutic use*
chemical_list: D018033:Antibodies, Bispecific; D000911:Antibodies, Monoclonal; D011868:Radioisotopes